Insight

VIPOR for Diffuse Large B-Cell Lymphoma involving the Central Nervous System

cfch.com.sg

Nov 22, 2024, 16:43

VIPOR for Diffuse Large B-Cell Lymphoma involving the Central Nervous System

Ajay Major shared a post on X:

“VIPOR R/R Primary central nervous system lymphoma /non-GC Secondary central nervous system lymphoma

Mark Roschewski, ASH24:

14 patients, most PCNSL
Objective response rate 62 percent / Complete remission 31 percent (ORR 67 percent / CR 22 percent if prior BTKi)
8 donation after circulatory death early, half d/t progression
71 percent diarrhea, 50 percent hypoK Multiple CNS-penetrating agents in VIPOR; should this be followed with consolidation? “

Ajay Major is an Assistant Professor of Medicine at the University of Colorado School of Medicine, specializing in lymphoma and CLL/SLL. He is the Founder and President of Pager Publications, as well as the Founder and Editor-in-Chief of in-House. Additionally, he serves as a Reviewer for the Bellevue Literary Review.

Ajay Major BTKi cancer complete remission hypoK Multiple CNS Mark Roschewski objective response rate OncoDaily Oncology Primary Central Nervous System Lymphoma Secondary central nervous system lymphoma ViPOR

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage